Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
JPMorgan to hold a virtual conference » 04:55
01/14/21
01/14
04:55
01/14/21
04:55
ABMD

Abiomed

$323.77 /

-1.24 (-0.38%)

, AGIO

Agios Pharmaceuticals

$46.48 /

-0.06 (-0.13%)

, AHCO

AdaptHealth

$36.94 /

+0.165 (+0.45%)

, BCAB

BioAtla

$44.92 /

+3.54 (+8.55%)

, NXGN

NextGen Healthcare

$21.27 /

+0.79 (+3.86%)

, OLMA

Olema Oncology

$41.90 /

-0.07 (-0.17%)

, PCRX

Pacira

$73.50 /

+0.39 (+0.53%)

, BIIB

Biogen

$266.71 /

-0.81 (-0.30%)

, ESPR

Esperion

$26.94 /

-3.335 (-11.02%)

, EXEL

Exelixis

$24.38 /

-0.845 (-3.35%)

, HQY

HealthEquity

$75.73 /

-0.25 (-0.33%)

, MORF

Morphic Holding

$30.30 /

+0.29 (+0.97%)

, NNOX

Nano-X Imaging

$54.30 /

+2.66 (+5.15%)

, SRPT

Sarepta

$87.22 /

+0.03 (+0.03%)

, SHC

Sotera Health

$25.01 /

-0.19 (-0.75%)

, RVNC

Revance

$29.02 /

-0.45 (-1.53%)

, RUBY

Rubius Therapeutics

$8.89 /

-0.28 (-3.05%)

, ZYME

Zymeworks

$52.97 /

-0.87 (-1.62%)

39th Annual Healthcare…

39th Annual Healthcare Virtual Conference will be held on January 11-14.

ShowHide Related Items >><<
ZYME Zymeworks
$52.97 /

-0.87 (-1.62%)

SRPT Sarepta
$87.22 /

+0.03 (+0.03%)

SHC Sotera Health
$25.01 /

-0.19 (-0.75%)

RVNC Revance
$29.02 /

-0.45 (-1.53%)

RUBY Rubius Therapeutics
$8.89 /

-0.28 (-3.05%)

PCRX Pacira
$73.50 /

+0.39 (+0.53%)

NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

MORF Morphic Holding
$30.30 /

+0.29 (+0.97%)

HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

EXEL Exelixis
$24.38 /

-0.845 (-3.35%)

ESPR Esperion
$26.94 /

-3.335 (-11.02%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

AHCO AdaptHealth
$36.94 /

+0.165 (+0.45%)

AGIO Agios Pharmaceuticals
$46.48 /

-0.06 (-0.13%)

ABMD Abiomed
$323.77 /

-1.24 (-0.38%)

ABMD Abiomed
$323.77 /

-1.24 (-0.38%)

12/21/20 SVB Leerink
Abiomed price target raised to $320 from $280 at SVB Leerink
12/14/20 Piper Sandler
Abiomed gets approval for XR sheath, says Piper Sandler
10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
AGIO Agios Pharmaceuticals
$46.48 /

-0.06 (-0.13%)

12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/22/20 Barclays
Agios could enter 2022 with a third fewer shares, says Barclays
AHCO AdaptHealth
$36.94 /

+0.165 (+0.45%)

01/07/21 Canaccord
AdaptHealth price target raised to $50 from $39 at Canaccord
12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
BCAB BioAtla
$44.92 /

+3.54 (+8.55%)

01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
NXGN NextGen Healthcare
$21.27 /

+0.79 (+3.86%)

10/23/20 SVB Leerink
NextGen Healthcare price target raised to $14 from $12 at SVB Leerink
10/23/20 Piper Sandler
NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler
07/31/20 Piper Sandler
NextGen Healthcare price target raised to $23 from $17 at Piper Sandler
06/02/20 Deutsche Bank
NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank
OLMA Olema Oncology
$41.90 /

-0.07 (-0.17%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
PCRX Pacira
$73.50 /

+0.39 (+0.53%)

01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
BIIB Biogen
$266.71 /

-0.81 (-0.30%)

01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
ESPR Esperion
$26.94 /

-3.335 (-11.02%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
EXEL Exelixis
$24.38 /

-0.845 (-3.35%)

12/14/20 William Blair
Calithera risk/reward attractive into CANTATA readout, says William Blair
10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

01/06/21 BTIG
HealthEquity initiated with a Neutral at BTIG
01/06/21 Deutsche Bank
HealthEquity price target raised to $77 from $60 at Deutsche Bank
12/08/20 Cantor Fitzgerald
HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald
12/08/20 JPMorgan
HealthEquity price target raised to $72 from $61 at JPMorgan
MORF Morphic Holding
$30.30 /

+0.29 (+0.97%)

10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

09/15/20 Cantor Fitzgerald
Cantor reiterates $70 target on Nano-X after 'unfounded' short report
09/15/20 Cantor Fitzgerald
Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald
09/15/20 Oppenheimer
Nano-X Imaging initiated with a Perform at Oppenheimer
09/15/20 Berenberg
Nano-X Imaging initiated with a Buy at Berenberg
SRPT Sarepta
$87.22 /

+0.03 (+0.03%)

01/12/21 Citi
Sarepta downgraded to Neutral from Buy at Citi
01/11/21
Fly Intel: Top five analyst downgrades
01/11/21 UBS
Sarepta downgraded to Neutral on 'unexpected negative' results at UBS
01/11/21 UBS
Sarepta downgraded to Neutral from Buy at UBS
SHC Sotera Health
$25.01 /

-0.19 (-0.75%)

01/13/21 Baird
Sotera Health initiated with an Outperform at Baird
12/15/20 KeyBanc
Sotera Health initiated with an Overweight at KeyBanc
12/15/20 JPMorgan
Sotera Health initiated with an Overweight at JPMorgan
12/15/20 Jefferies
Sotera Health initiated with a Buy at Jefferies
RVNC Revance
$29.02 /

-0.45 (-1.53%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
RUBY Rubius Therapeutics
$8.89 /

-0.28 (-3.05%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
ZYME Zymeworks
$52.97 /

-0.87 (-1.62%)

01/12/21 SVB Leerink
Zymeworks price target raised to $66 from $45 at SVB Leerink
01/12/21 Wells Fargo
Zymeworks price target raised to $71 from $58 at Wells Fargo
09/29/20 JPMorgan
Zymeworks resumed with a Neutral at JPMorgan
08/06/20
Fly Intel: Top analyst initiations
ZYME Zymeworks
$52.97 /

-0.87 (-1.62%)

SRPT Sarepta
$87.22 /

+0.03 (+0.03%)

SHC Sotera Health
$25.01 /

-0.19 (-0.75%)

RVNC Revance
$29.02 /

-0.45 (-1.53%)

RUBY Rubius Therapeutics
$8.89 /

-0.28 (-3.05%)

PCRX Pacira
$73.50 /

+0.39 (+0.53%)

NXGN NextGen Healthcare
$21.27 /

+0.79 (+3.86%)

NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

MORF Morphic Holding
$30.30 /

+0.29 (+0.97%)

HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

EXEL Exelixis
$24.38 /

-0.845 (-3.35%)

ESPR Esperion
$26.94 /

-3.335 (-11.02%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

AHCO AdaptHealth
$36.94 /

+0.165 (+0.45%)

AGIO Agios Pharmaceuticals
$46.48 /

-0.06 (-0.13%)

ABMD Abiomed
$323.77 /

-1.24 (-0.38%)

  • 06
    Jan
  • 15
    Dec
  • 16
    Dec
  • 19
    Nov
  • 20
    Nov
  • 03
    Sep
  • 21
    Aug
  • 09
    Jul
  • 01
    Jul
  • 12
    Feb
  • 23
    Jan
NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

SRPT Sarepta
$87.22 /

+0.03 (+0.03%)

RVNC Revance
$29.02 /

-0.45 (-1.53%)

OLMA Olema Oncology
$41.90 /

-0.07 (-0.17%)

NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

ESPR Esperion
$26.94 /

-3.335 (-11.02%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

BCAB BioAtla
$44.92 /

+3.54 (+8.55%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

ESPR Esperion
$26.94 /

-3.335 (-11.02%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

AHCO AdaptHealth
$36.94 /

+0.165 (+0.45%)

Wednesday
Conference/Events
JPMorgan to hold a virtual conference » 04:55
01/13/21
01/13
04:55
01/13/21
04:55
ABMD

Abiomed

$324.65 /

+0.28 (+0.09%)

, AGIO

Agios Pharmaceuticals

$46.54 /

-0.19 (-0.41%)

, AHCO

AdaptHealth

$36.78 /

-0.405 (-1.09%)

, BCAB

BioAtla

$41.38 /

+1.38 (+3.45%)

, NXGN

NextGen Healthcare

$20.50 /

+0.89 (+4.54%)

, OLMA

Olema Oncology

$41.97 /

+0.84 (+2.04%)

, PCRX

Pacira

$73.11 /

+1.46 (+2.04%)

, BIIB

Biogen

$267.44 /

-0.13 (-0.05%)

, ESPR

Esperion

$30.28 /

-1.01 (-3.23%)

, EXEL

Exelixis

$25.23 /

+1.1 (+4.56%)

, HQY

HealthEquity

$75.95 /

+1.83 (+2.47%)

, MORF

Morphic Holding

$30.12 /

+0.27 (+0.90%)

, NNOX

Nano-X Imaging

$51.61 /

+0.22 (+0.43%)

, SRPT

Sarepta

$87.32 /

-2.46 (-2.74%)

, SHC

Sotera Health

$25.20 /

-0.39 (-1.52%)

, RVNC

Revance

$29.47 /

+0.46 (+1.59%)

, RUBY

Rubius Therapeutics

$9.16 /

+0.12 (+1.33%)

, ZYME

Zymeworks

$53.99 /

-2.49 (-4.41%)

39th Annual Healthcare…

39th Annual Healthcare Virtual Conference will be held on January 11-14.

ShowHide Related Items >><<
ZYME Zymeworks
$53.99 /

-2.49 (-4.41%)

SRPT Sarepta
$87.32 /

-2.46 (-2.74%)

SHC Sotera Health
$25.20 /

-0.39 (-1.52%)

RVNC Revance
$29.47 /

+0.46 (+1.59%)

RUBY Rubius Therapeutics
$9.16 /

+0.12 (+1.33%)

PCRX Pacira
$73.11 /

+1.46 (+2.04%)

NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

MORF Morphic Holding
$30.12 /

+0.27 (+0.90%)

HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

EXEL Exelixis
$25.23 /

+1.1 (+4.56%)

ESPR Esperion
$30.28 /

-1.01 (-3.23%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

AHCO AdaptHealth
$36.78 /

-0.405 (-1.09%)

AGIO Agios Pharmaceuticals
$46.54 /

-0.19 (-0.41%)

ABMD Abiomed
$324.65 /

+0.28 (+0.09%)

ABMD Abiomed
$324.65 /

+0.28 (+0.09%)

12/21/20 SVB Leerink
Abiomed price target raised to $320 from $280 at SVB Leerink
12/14/20 Piper Sandler
Abiomed gets approval for XR sheath, says Piper Sandler
10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
AGIO Agios Pharmaceuticals
$46.54 /

-0.19 (-0.41%)

12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/22/20 Barclays
Agios could enter 2022 with a third fewer shares, says Barclays
AHCO AdaptHealth
$36.78 /

-0.405 (-1.09%)

01/07/21 Canaccord
AdaptHealth price target raised to $50 from $39 at Canaccord
12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
BCAB BioAtla
$41.38 /

+1.38 (+3.45%)

01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
NXGN NextGen Healthcare
$20.50 /

+0.89 (+4.54%)

10/23/20 SVB Leerink
NextGen Healthcare price target raised to $14 from $12 at SVB Leerink
10/23/20 Piper Sandler
NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler
07/31/20 Piper Sandler
NextGen Healthcare price target raised to $23 from $17 at Piper Sandler
06/02/20 Deutsche Bank
NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank
OLMA Olema Oncology
$41.97 /

+0.84 (+2.04%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
PCRX Pacira
$73.11 /

+1.46 (+2.04%)

01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
BIIB Biogen
$267.44 /

-0.13 (-0.05%)

01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
ESPR Esperion
$30.28 /

-1.01 (-3.23%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
EXEL Exelixis
$25.23 /

+1.1 (+4.56%)

12/14/20 William Blair
Calithera risk/reward attractive into CANTATA readout, says William Blair
10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

01/06/21 BTIG
HealthEquity initiated with a Neutral at BTIG
01/06/21 Deutsche Bank
HealthEquity price target raised to $77 from $60 at Deutsche Bank
12/08/20 Cantor Fitzgerald
HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald
12/08/20 JPMorgan
HealthEquity price target raised to $72 from $61 at JPMorgan
MORF Morphic Holding
$30.12 /

+0.27 (+0.90%)

10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

09/15/20 Cantor Fitzgerald
Cantor reiterates $70 target on Nano-X after 'unfounded' short report
09/15/20 Cantor Fitzgerald
Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald
09/15/20 Oppenheimer
Nano-X Imaging initiated with a Perform at Oppenheimer
09/15/20 Berenberg
Nano-X Imaging initiated with a Buy at Berenberg
SRPT Sarepta
$87.32 /

-2.46 (-2.74%)

01/12/21 Citi
Sarepta downgraded to Neutral from Buy at Citi
01/11/21
Fly Intel: Top five analyst downgrades
01/11/21 UBS
Sarepta downgraded to Neutral on 'unexpected negative' results at UBS
01/11/21 UBS
Sarepta downgraded to Neutral from Buy at UBS
SHC Sotera Health
$25.20 /

-0.39 (-1.52%)

12/15/20 KeyBanc
Sotera Health initiated with an Overweight at KeyBanc
12/15/20 JPMorgan
Sotera Health initiated with an Overweight at JPMorgan
12/15/20 Jefferies
Sotera Health initiated with a Buy at Jefferies
12/15/20 Citi
Sotera Health initiated with a Buy at Citi
RVNC Revance
$29.47 /

+0.46 (+1.59%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
RUBY Rubius Therapeutics
$9.16 /

+0.12 (+1.33%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
ZYME Zymeworks
$53.99 /

-2.49 (-4.41%)

01/12/21 SVB Leerink
Zymeworks price target raised to $66 from $45 at SVB Leerink
01/12/21 Wells Fargo
Zymeworks price target raised to $71 from $58 at Wells Fargo
09/29/20 JPMorgan
Zymeworks resumed with a Neutral at JPMorgan
08/06/20
Fly Intel: Top analyst initiations
ZYME Zymeworks
$53.99 /

-2.49 (-4.41%)

SRPT Sarepta
$87.32 /

-2.46 (-2.74%)

SHC Sotera Health
$25.20 /

-0.39 (-1.52%)

RVNC Revance
$29.47 /

+0.46 (+1.59%)

RUBY Rubius Therapeutics
$9.16 /

+0.12 (+1.33%)

PCRX Pacira
$73.11 /

+1.46 (+2.04%)

NXGN NextGen Healthcare
$20.50 /

+0.89 (+4.54%)

NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

MORF Morphic Holding
$30.12 /

+0.27 (+0.90%)

HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

EXEL Exelixis
$25.23 /

+1.1 (+4.56%)

ESPR Esperion
$30.28 /

-1.01 (-3.23%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

AHCO AdaptHealth
$36.78 /

-0.405 (-1.09%)

AGIO Agios Pharmaceuticals
$46.54 /

-0.19 (-0.41%)

ABMD Abiomed
$324.65 /

+0.28 (+0.09%)

  • 06
    Jan
  • 15
    Dec
  • 16
    Dec
  • 19
    Nov
  • 20
    Nov
  • 03
    Sep
  • 21
    Aug
  • 09
    Jul
  • 01
    Jul
  • 12
    Feb
  • 23
    Jan
NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

SRPT Sarepta
$87.32 /

-2.46 (-2.74%)

RVNC Revance
$29.47 /

+0.46 (+1.59%)

OLMA Olema Oncology
$41.97 /

+0.84 (+2.04%)

NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

ESPR Esperion
$30.28 /

-1.01 (-3.23%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

BCAB BioAtla
$41.38 /

+1.38 (+3.45%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

ESPR Esperion
$30.28 /

-1.01 (-3.23%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

AHCO AdaptHealth
$36.78 /

-0.405 (-1.09%)

Tuesday
Conference/Events
JPMorgan to hold a virtual conference » 04:55
01/12/21
01/12
04:55
01/12/21
04:55
ABMD

Abiomed

$324.31 /

+0.31 (+0.10%)

, AGIO

Agios Pharmaceuticals

$46.71 /

+0.81 (+1.76%)

, AHCO

AdaptHealth

$37.18 /

-1.06 (-2.77%)

, BCAB

BioAtla

$40.00 /

+1.79 (+4.68%)

, NXGN

NextGen Healthcare

$19.60 /

-0.26 (-1.31%)

, OLMA

Olema Oncology

$41.65 /

-0.84 (-1.98%)

, PCRX

Pacira

$71.65 /

+1.58 (+2.25%)

, BIIB

Biogen

$267.53 /

+15.17 (+6.01%)

, ESPR

Esperion

$31.29 /

+0.25 (+0.81%)

, EXEL

Exelixis

$24.13 /

+1.3 (+5.69%)

, HQY

HealthEquity

$74.12 /

-1.03 (-1.37%)

, MORF

Morphic Holding

$29.83 /

-0.64 (-2.10%)

, NNOX

Nano-X Imaging

$51.39 /

-1.625 (-3.07%)

, SRPT

Sarepta

$89.78 /

+7.48 (+9.09%)

, SHC

Sotera Health

$25.59 /

+0.59 (+2.36%)

, RVNC

Revance

$29.00 /

-0.41 (-1.39%)

, RUBY

Rubius Therapeutics

$9.03 /

-0.47 (-4.95%)

, ZYME

Zymeworks

$56.48 /

-0.45 (-0.79%)

39th Annual Healthcare…

39th Annual Healthcare Virtual Conference will be held on January 11-14.

ShowHide Related Items >><<
ZYME Zymeworks
$56.48 /

-0.45 (-0.79%)

SRPT Sarepta
$89.78 /

+7.48 (+9.09%)

SHC Sotera Health
$25.59 /

+0.59 (+2.36%)

RVNC Revance
$29.00 /

-0.41 (-1.39%)

RUBY Rubius Therapeutics
$9.03 /

-0.47 (-4.95%)

PCRX Pacira
$71.65 /

+1.58 (+2.25%)

NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

MORF Morphic Holding
$29.83 /

-0.64 (-2.10%)

HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

EXEL Exelixis
$24.13 /

+1.3 (+5.69%)

ESPR Esperion
$31.29 /

+0.25 (+0.81%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

AHCO AdaptHealth
$37.18 /

-1.06 (-2.77%)

AGIO Agios Pharmaceuticals
$46.71 /

+0.81 (+1.76%)

ABMD Abiomed
$324.31 /

+0.31 (+0.10%)

ABMD Abiomed
$324.31 /

+0.31 (+0.10%)

12/21/20 SVB Leerink
Abiomed price target raised to $320 from $280 at SVB Leerink
12/14/20 Piper Sandler
Abiomed gets approval for XR sheath, says Piper Sandler
10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
AGIO Agios Pharmaceuticals
$46.71 /

+0.81 (+1.76%)

12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/22/20 Barclays
Agios could enter 2022 with a third fewer shares, says Barclays
AHCO AdaptHealth
$37.18 /

-1.06 (-2.77%)

01/07/21 Canaccord
AdaptHealth price target raised to $50 from $39 at Canaccord
12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
BCAB BioAtla
$40.00 /

+1.79 (+4.68%)

01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
NXGN NextGen Healthcare
$19.60 /

-0.26 (-1.31%)

10/23/20 SVB Leerink
NextGen Healthcare price target raised to $14 from $12 at SVB Leerink
10/23/20 Piper Sandler
NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler
07/31/20 Piper Sandler
NextGen Healthcare price target raised to $23 from $17 at Piper Sandler
06/02/20 Deutsche Bank
NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank
OLMA Olema Oncology
$41.65 /

-0.84 (-1.98%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
PCRX Pacira
$71.65 /

+1.58 (+2.25%)

01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
BIIB Biogen
$267.53 /

+15.17 (+6.01%)

01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
ESPR Esperion
$31.29 /

+0.25 (+0.81%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
EXEL Exelixis
$24.13 /

+1.3 (+5.69%)

12/14/20 William Blair
Calithera risk/reward attractive into CANTATA readout, says William Blair
10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

01/06/21 BTIG
HealthEquity initiated with a Neutral at BTIG
01/06/21 Deutsche Bank
HealthEquity price target raised to $77 from $60 at Deutsche Bank
12/08/20 Cantor Fitzgerald
HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald
12/08/20 JPMorgan
HealthEquity price target raised to $72 from $61 at JPMorgan
MORF Morphic Holding
$29.83 /

-0.64 (-2.10%)

10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

09/15/20 Cantor Fitzgerald
Cantor reiterates $70 target on Nano-X after 'unfounded' short report
09/15/20 Cantor Fitzgerald
Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald
09/15/20 Oppenheimer
Nano-X Imaging initiated with a Perform at Oppenheimer
09/15/20 Berenberg
Nano-X Imaging initiated with a Buy at Berenberg
SRPT Sarepta
$89.78 /

+7.48 (+9.09%)

01/11/21
Fly Intel: Top five analyst downgrades
01/11/21 UBS
Sarepta downgraded to Neutral on 'unexpected negative' results at UBS
01/11/21 UBS
Sarepta downgraded to Neutral from Buy at UBS
01/08/21 Chardan
Solid Biosciences selloff on Sarepta news a buying opportunity, says Chardan
SHC Sotera Health
$25.59 /

+0.59 (+2.36%)

12/15/20 KeyBanc
Sotera Health initiated with an Overweight at KeyBanc
12/15/20 JPMorgan
Sotera Health initiated with an Overweight at JPMorgan
12/15/20 Jefferies
Sotera Health initiated with a Buy at Jefferies
12/15/20 Citi
Sotera Health initiated with a Buy at Citi
RVNC Revance
$29.00 /

-0.41 (-1.39%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
RUBY Rubius Therapeutics
$9.03 /

-0.47 (-4.95%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
ZYME Zymeworks
$56.48 /

-0.45 (-0.79%)

09/29/20 JPMorgan
Zymeworks resumed with a Neutral at JPMorgan
08/06/20
Fly Intel: Top analyst initiations
08/06/20 SVB Leerink
SVB Leerink bullish on Zymeworks, initiates with an Outperform
08/06/20 SVB Leerink
Zymeworks initiated with an Outperform at SVB Leerink
ZYME Zymeworks
$56.48 /

-0.45 (-0.79%)

SRPT Sarepta
$89.78 /

+7.48 (+9.09%)

SHC Sotera Health
$25.59 /

+0.59 (+2.36%)

RVNC Revance
$29.00 /

-0.41 (-1.39%)

RUBY Rubius Therapeutics
$9.03 /

-0.47 (-4.95%)

PCRX Pacira
$71.65 /

+1.58 (+2.25%)

NXGN NextGen Healthcare
$19.60 /

-0.26 (-1.31%)

NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

MORF Morphic Holding
$29.83 /

-0.64 (-2.10%)

HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

EXEL Exelixis
$24.13 /

+1.3 (+5.69%)

ESPR Esperion
$31.29 /

+0.25 (+0.81%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

AHCO AdaptHealth
$37.18 /

-1.06 (-2.77%)

AGIO Agios Pharmaceuticals
$46.71 /

+0.81 (+1.76%)

ABMD Abiomed
$324.31 /

+0.31 (+0.10%)

  • 06
    Jan
  • 15
    Dec
  • 16
    Dec
  • 19
    Nov
  • 20
    Nov
  • 03
    Sep
  • 21
    Aug
  • 09
    Jul
  • 01
    Jul
  • 12
    Feb
  • 23
    Jan
NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

SRPT Sarepta
$89.78 /

+7.48 (+9.09%)

RVNC Revance
$29.00 /

-0.41 (-1.39%)

OLMA Olema Oncology
$41.65 /

-0.84 (-1.98%)

NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

ESPR Esperion
$31.29 /

+0.25 (+0.81%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

BCAB BioAtla
$40.00 /

+1.79 (+4.68%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

ESPR Esperion
$31.29 /

+0.25 (+0.81%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

AHCO AdaptHealth
$37.18 /

-1.06 (-2.77%)

Over a week ago
Conference/Events
JPMorgan to hold a virtual conference » 09:44
01/11/21
01/11
09:44
01/11/21
09:44
ABMD

Abiomed

$324.00 /

+ (+0.00%)

, AGIO

Agios Pharmaceuticals

$45.85 /

-0.05 (-0.11%)

, AHCO

AdaptHealth

$38.24 /

+ (+0.00%)

, BCAB

BioAtla

$38.22 /

+0.01 (+0.03%)

, NXGN

NextGen Healthcare

$19.92 /

+0.06 (+0.30%)

, OLMA

Olema Oncology

$42.48 /

-0.01 (-0.02%)

, PCRX

Pacira

$70.03 /

-0.04 (-0.06%)

, BIIB

Biogen

$252.57 /

+0.21 (+0.08%)

, ESPR

Esperion

$31.04 /

+ (+0.00%)

, EXEL

Exelixis

$22.84 /

+0.01 (+0.04%)

, HQY

HealthEquity

$75.22 /

+0.07 (+0.09%)

, MORF

Morphic Holding

$30.47 /

+ (+0.00%)

, NNOX

Nano-X Imaging

$53.02 /

+ (+0.00%)

, SRPT

Sarepta

$82.30 /

+ (+0.00%)

, SHC

Sotera Health

$25.00 /

+ (+0.00%)

, RVNC

Revance

$29.41 /

+ (+0.00%)

, RUBY

Rubius Therapeutics

$9.50 /

+ (+0.00%)

, ZYME

Zymeworks

$56.95 /

+0.02 (+0.04%)

39th Annual Healthcare…

39th Annual Healthcare Virtual Conference will be held on January 11-14.

ShowHide Related Items >><<
ZYME Zymeworks
$56.95 /

+0.02 (+0.04%)

SRPT Sarepta
$82.30 /

+ (+0.00%)

SHC Sotera Health
$25.00 /

+ (+0.00%)

RVNC Revance
$29.41 /

+ (+0.00%)

RUBY Rubius Therapeutics
$9.50 /

+ (+0.00%)

PCRX Pacira
$70.03 /

-0.04 (-0.06%)

NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

MORF Morphic Holding
$30.47 /

+ (+0.00%)

HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

EXEL Exelixis
$22.84 /

+0.01 (+0.04%)

ESPR Esperion
$31.04 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

AHCO AdaptHealth
$38.24 /

+ (+0.00%)

AGIO Agios Pharmaceuticals
$45.85 /

-0.05 (-0.11%)

ABMD Abiomed
$324.00 /

+ (+0.00%)

ABMD Abiomed
$324.00 /

+ (+0.00%)

12/21/20 SVB Leerink
Abiomed price target raised to $320 from $280 at SVB Leerink
12/14/20 Piper Sandler
Abiomed gets approval for XR sheath, says Piper Sandler
10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
AGIO Agios Pharmaceuticals
$45.85 /

-0.05 (-0.11%)

12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/22/20 Barclays
Agios could enter 2022 with a third fewer shares, says Barclays
AHCO AdaptHealth
$38.24 /

+ (+0.00%)

01/07/21 Canaccord
AdaptHealth price target raised to $50 from $39 at Canaccord
12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
BCAB BioAtla
$38.22 /

+0.01 (+0.03%)

01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
NXGN NextGen Healthcare
$19.92 /

+0.06 (+0.30%)

10/23/20 SVB Leerink
NextGen Healthcare price target raised to $14 from $12 at SVB Leerink
10/23/20 Piper Sandler
NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler
07/31/20 Piper Sandler
NextGen Healthcare price target raised to $23 from $17 at Piper Sandler
06/02/20 Deutsche Bank
NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank
OLMA Olema Oncology
$42.48 /

-0.01 (-0.02%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
PCRX Pacira
$70.03 /

-0.04 (-0.06%)

01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
BIIB Biogen
$252.57 /

+0.21 (+0.08%)

12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
12/01/20 Citi
Sage Therapeutics price target lowered to $93 from $100 at Citi
ESPR Esperion
$31.04 /

+ (+0.00%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
EXEL Exelixis
$22.84 /

+0.01 (+0.04%)

12/14/20 William Blair
Calithera risk/reward attractive into CANTATA readout, says William Blair
10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

01/06/21 BTIG
HealthEquity initiated with a Neutral at BTIG
01/06/21 Deutsche Bank
HealthEquity price target raised to $77 from $60 at Deutsche Bank
12/08/20 Cantor Fitzgerald
HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald
12/08/20 JPMorgan
HealthEquity price target raised to $72 from $61 at JPMorgan
MORF Morphic Holding
$30.47 /

+ (+0.00%)

10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

09/15/20 Cantor Fitzgerald
Cantor reiterates $70 target on Nano-X after 'unfounded' short report
09/15/20 Cantor Fitzgerald
Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald
09/15/20 Oppenheimer
Nano-X Imaging initiated with a Perform at Oppenheimer
09/15/20 Berenberg
Nano-X Imaging initiated with a Buy at Berenberg
SRPT Sarepta
$82.30 /

+ (+0.00%)

01/11/21 UBS
Sarepta downgraded to Neutral on 'unexpected negative' results at UBS
01/11/21 UBS
Sarepta downgraded to Neutral from Buy at UBS
01/08/21 Chardan
Solid Biosciences selloff on Sarepta news a buying opportunity, says Chardan
01/08/21 JPMorgan
Sarepta downgraded to Underweight from Overweight at JPMorgan
SHC Sotera Health
$25.00 /

+ (+0.00%)

12/15/20 KeyBanc
Sotera Health initiated with an Overweight at KeyBanc
12/15/20 JPMorgan
Sotera Health initiated with an Overweight at JPMorgan
12/15/20 Jefferies
Sotera Health initiated with a Buy at Jefferies
12/15/20 Citi
Sotera Health initiated with a Buy at Citi
RVNC Revance
$29.41 /

+ (+0.00%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
RUBY Rubius Therapeutics
$9.50 /

+ (+0.00%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
ZYME Zymeworks
$56.95 /

+0.02 (+0.04%)

09/29/20 JPMorgan
Zymeworks resumed with a Neutral at JPMorgan
08/06/20
Fly Intel: Top analyst initiations
08/06/20 SVB Leerink
SVB Leerink bullish on Zymeworks, initiates with an Outperform
08/06/20 SVB Leerink
Zymeworks initiated with an Outperform at SVB Leerink
ZYME Zymeworks
$56.95 /

+0.02 (+0.04%)

SRPT Sarepta
$82.30 /

+ (+0.00%)

SHC Sotera Health
$25.00 /

+ (+0.00%)

RVNC Revance
$29.41 /

+ (+0.00%)

RUBY Rubius Therapeutics
$9.50 /

+ (+0.00%)

PCRX Pacira
$70.03 /

-0.04 (-0.06%)

NXGN NextGen Healthcare
$19.92 /

+0.06 (+0.30%)

NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

MORF Morphic Holding
$30.47 /

+ (+0.00%)

HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

EXEL Exelixis
$22.84 /

+0.01 (+0.04%)

ESPR Esperion
$31.04 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

AHCO AdaptHealth
$38.24 /

+ (+0.00%)

AGIO Agios Pharmaceuticals
$45.85 /

-0.05 (-0.11%)

ABMD Abiomed
$324.00 /

+ (+0.00%)

  • 06
    Jan
  • 15
    Dec
  • 16
    Dec
  • 19
    Nov
  • 20
    Nov
  • 03
    Sep
  • 21
    Aug
  • 09
    Jul
  • 01
    Jul
  • 12
    Feb
  • 23
    Jan
NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

SRPT Sarepta
$82.30 /

+ (+0.00%)

RVNC Revance
$29.41 /

+ (+0.00%)

OLMA Olema Oncology
$42.48 /

-0.01 (-0.02%)

NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

ESPR Esperion
$31.04 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

BCAB BioAtla
$38.22 /

+0.01 (+0.03%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

ESPR Esperion
$31.04 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

AHCO AdaptHealth
$38.24 /

+ (+0.00%)

Recommendations
AdaptHealth price target raised to $50 from $39 at Canaccord » 15:08
01/07/21
01/07
15:08
01/07/21
15:08
AHCO

AdaptHealth

$38.52 /

+0.35 (+0.92%)

Canaccord analyst Richard…

Canaccord analyst Richard Close raised the firm's price target on AdaptHealth to $50 from $39 and keeps a Buy rating on the shares while calling it a focus stock for 2021. In 2021, he expects to see accelerated adoption of disruptive models in healthcare services and expects demand for next generation companies to remain high, Close tells investors.

ShowHide Related Items >><<
AHCO AdaptHealth
$38.52 /

+0.35 (+0.92%)

AHCO AdaptHealth
$38.52 /

+0.35 (+0.92%)

12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
12/02/20 RBC Capital
AdaptHealth price target raised to $50 from $36 at RBC Capital
AHCO AdaptHealth
$38.52 /

+0.35 (+0.92%)

  • 06
    Jan
  • 15
    Dec
  • 03
    Sep
  • 01
    Jul
AHCO AdaptHealth
$38.52 /

+0.35 (+0.92%)

Syndicate
AdaptHealth 8M share Secondary priced at $33.00 » 06:23
01/06/21
01/06
06:23
01/06/21
06:23
AHCO

AdaptHealth

$33.87 /

-1.91 (-5.34%)

Deutsche Bank, Jefferies,…

Deutsche Bank, Jefferies, BofA and Truist acted as joint book running managers for the offering.

ShowHide Related Items >><<
AHCO AdaptHealth
$33.87 /

-1.91 (-5.34%)

AHCO AdaptHealth
$33.87 /

-1.91 (-5.34%)

12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
12/02/20 RBC Capital
AdaptHealth price target raised to $50 from $36 at RBC Capital
AHCO AdaptHealth
$33.87 /

-1.91 (-5.34%)

  • 06
    Jan
  • 15
    Dec
  • 03
    Sep
  • 01
    Jul
AHCO AdaptHealth
$33.87 /

-1.91 (-5.34%)

Hot Stocks
AdaptHealth falls 5% to $34.00 per share after equity offering  18:54
01/04/21
01/04
18:54
01/04/21
18:54
AHCO

AdaptHealth

$35.75 /

-1.81 (-4.82%)

 
ShowHide Related Items >><<
AHCO AdaptHealth
$35.75 /

-1.81 (-4.82%)

AHCO AdaptHealth
$35.75 /

-1.81 (-4.82%)

12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
12/02/20 RBC Capital
AdaptHealth price target raised to $50 from $36 at RBC Capital
AHCO AdaptHealth
$35.75 /

-1.81 (-4.82%)

  • 15
    Dec
  • 03
    Sep
  • 01
    Jul
AHCO AdaptHealth
$35.75 /

-1.81 (-4.82%)

Syndicate
AdaptHealth announces offering of 8M shares of Class A common stock » 18:42
01/04/21
01/04
18:42
01/04/21
18:42
AHCO

AdaptHealth

$35.75 /

-1.81 (-4.82%)

AdaptHealth announced…

AdaptHealth announced that it has commenced an underwritten public offering of 7M shares of its Class A Common Stock, and certain selling stockholders intend to offer and sell an additional 1M shares of the company's Class A Common Stock, subject to market and other conditions. The company intends to use approximately half of the net proceeds of the shares offered by it in this offering, together with senior secured term loan borrowings, the net proceeds from the issuance of unsecured senior notes and cash on hand, to finance the company's previously announced acquisition of AeroCare Holdings, and to pay related fees and expenses, and the remainder for general corporate purposes, which may include future acquisitions and other business opportunities, capital expenditures and working capital. The company will not receive any proceeds from the sale of Class A Common Stock by the selling stockholders. The closing of the AeroCare acquisition is not dependent on the consummation of the offering, and the consummation of the offering is not dependent on the closing of the acquisition. Deutsche Bank Securities, Jefferies, BofA Securities and Truist Securities are acting as lead book-running managers for the offering. Baird, RBC Capital Markets, Stifel, and UBS Investment Bank are acting as joint book-running managers for the offering

ShowHide Related Items >><<
AHCO AdaptHealth
$35.75 /

-1.81 (-4.82%)

AHCO AdaptHealth
$35.75 /

-1.81 (-4.82%)

12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
12/02/20 RBC Capital
AdaptHealth price target raised to $50 from $36 at RBC Capital
AHCO AdaptHealth
$35.75 /

-1.81 (-4.82%)

  • 15
    Dec
  • 03
    Sep
  • 01
    Jul
AHCO AdaptHealth
$35.75 /

-1.81 (-4.82%)

Over a month ago
Syndicate
AdaptHealth 2M share Block Trade priced at $35.15 » 07:41
12/15/20
12/15
07:41
12/15/20
07:41
AHCO

AdaptHealth

$36.66 /

-0.88 (-2.34%)

The deal range was…

The deal range was $35.15-$35.75. Jefferies acted as sole book running manager for the offering.

ShowHide Related Items >><<
AHCO AdaptHealth
$36.66 /

-0.88 (-2.34%)

AHCO AdaptHealth
$36.66 /

-0.88 (-2.34%)

12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
12/02/20 RBC Capital
AdaptHealth price target raised to $50 from $36 at RBC Capital
AHCO AdaptHealth
$36.66 /

-0.88 (-2.34%)

  • 15
    Dec
  • 03
    Sep
  • 01
    Jul
AHCO AdaptHealth
$36.66 /

-0.88 (-2.34%)

Syndicate
AdaptHealth 2M share Block Trade; price range $35.15-$35.75 » 17:03
12/14/20
12/14
17:03
12/14/20
17:03
AHCO

AdaptHealth

$36.66 /

-0.88 (-2.34%)

Jefferies is acting as…

Jefferies is acting as sole book running manager for the offering.

ShowHide Related Items >><<
AHCO AdaptHealth
$36.66 /

-0.88 (-2.34%)

AHCO AdaptHealth
$36.66 /

-0.88 (-2.34%)

12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
12/02/20 RBC Capital
AdaptHealth price target raised to $50 from $36 at RBC Capital
AHCO AdaptHealth
$36.66 /

-0.88 (-2.34%)

  • 03
    Sep
  • 01
    Jul
AHCO AdaptHealth
$36.66 /

-0.88 (-2.34%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.